Skip to main content
From Bio Co., Ltd. logo

From Bio Co., Ltd. — Investor Relations & Filings

Ticker · 377220 ISIN · KR7377220009 KO Manufacturing
Open in API
Filings indexed 112 across all filing types
Latest filing 2021-09-13 Capital/Financing Update
Country KR South Korea
Listing KO 377220

About From Bio Co., Ltd.

https://frombio-company.co.kr/default/e…

From Bio Co., Ltd. is a healthcare company specializing in the research, development, manufacturing, and sale of health functional foods and dietary supplements. The company operates across the entire value chain, from sourcing new raw materials to production in its GMP-certified facility. A significant focus is placed on research and development through its specialized Food, Bio, and New Drug laboratories. These divisions work on discovering and verifying novel functional ingredients for health foods while also developing new pharmaceuticals, including treatments for alopecia and first-in-class drugs. The product portfolio addresses specific health needs such as joint health (Boswellia), stomach comfort (Mastic Gum), eye health (Bilberry), and body fat reduction (Wild Mango), emphasizing the use of natural, plant-based ingredients.

Recent filings

Filing Released Lang Actions
[기재정정]투자설명서
Capital/Financing Update Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a 'Prospectus' (투자설명서) filed by FromBio Co., Ltd. It details amendments to the offering price, number of shares, and related financial terms following the finalization of the public offering price. In the context of Korean regulatory filings (DART), this is a formal amendment to a securities registration statement/prospectus. Since it is a detailed regulatory filing regarding capital raising and offering terms, it falls under 'Regulatory Filings' (RNS) as the most appropriate category for this type of formal amendment document.
2021-09-13 Korean
투자설명서
Capital/Financing Update Classification · 95% confidence The document is a '투자설명서' (Investment Prospectus) for '주식회사 프롬바이오' (FromBio Co., Ltd.), dated September 10, 2021. It contains detailed information regarding a public offering of 3,000,000 shares, including offering price, subscription period, and extensive risk factors (business and company-specific risks). This is a formal regulatory document filed for the purpose of a securities offering, which falls under the category of a Prospectus/Proxy Solicitation/Information Statement. Given the specific options provided, 'PSI' (Proxy Solicitation & Information Statement) is the most appropriate classification for a formal investment prospectus document.
2021-09-10 Korean
[기재정정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고(보고)' (Amendment to Securities Registration Statement for Equity Securities) filed by '주식회사 프롬바이오'. This is a formal regulatory filing submitted to the financial authorities (DART system in Korea) to correct or supplement information in a previously filed securities registration statement. It contains detailed sections on business risks, market competition, and production processes, which are standard components of a formal securities registration document. It is not a report publication announcement (RPA) because it is the actual regulatory filing document itself, nor is it an annual report (10-K) or interim report (IR). Therefore, it falls under the 'Regulatory Filings' category.
2021-09-06 Korean
증권신고서(지분증권)
Share Issue/Capital Change Classification · 98% confidence The document is a '증권신고서' (Securities Registration Statement) filed by '주식회사 프롬바이오' (FromBio Co., Ltd.) with the Financial Services Commission (FSC) in South Korea. It contains detailed information regarding the issuance of equity securities, investment risks, business overview, and financial information, which is characteristic of a formal registration statement for a public offering (IPO or capital raise). In the context of the provided filing categories, this document serves as a formal regulatory filing for a securities offering, which is best classified as a Regulatory Filing (RNS) as it does not fit into the specific categories like 10-K (Annual Report) or ER (Earnings Release).
2021-08-19 Korean
감사보고서 (2020.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'FromBio' (프롬바이오) for the fiscal year ending December 31, 2020. It includes the independent auditor's opinion, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. It is not an Annual Report (10-K) as it lacks the comprehensive management discussion and analysis (MD&A) and business overview typically found in a full annual report, focusing specifically on the audit and financial statements. FY 2020
2021-04-01 Korean
감사보고서 (2019.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for the company 'FromBio' (주식회사 프롬바이오). It includes the independent auditor's report, balance sheet, income statement, statement of changes in equity, cash flow statement, and detailed notes to the financial statements for the fiscal years 2018 and 2019. Since it contains full financial statements and audit results rather than just an announcement or a summary, it is classified as an Audit Report. FY 2019
2020-04-01 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.